H. Nüßlein

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

H. Nüßlein, Rieke Alten, Mauro Galeazzi et al. · BMC Musculoskeletal Disorders · 2014 · 49 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study

Rieke Alten, H. Nüßlein, Xavier Mariette et al. · RMD Open · 2017 · 43 citations · Full text

Life Sciences, Internal Medicine, Pharmacotherapy +17

Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

H. Nüßlein, Rieke Alten, Mauro Galeazzi et al. · BMC Musculoskeletal Disorders · 2015 · 42 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study

Rieke Alten, Xavier Mariette, Hanns‐Martin Lorenz et al. · Clinical Rheumatology · 2019 · 34 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.

H. Nüßlein, Rieke Alten, Mauro Galeazzi et al. · PubMed · 2016 · 32 citations

Pharmacy, Pharmacotherapy, Drug Utilization Review +13